Allosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
List view / Grid view
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
In this interview we discuss with Alder Therapeutics regenerative cell therapy development through a proactive strategy, addressing manufacturing challenges early and ensuring a streamlined process. We explore an approach in pluripotent stem cell therapy development which eliminates complexities, minimises costs and expedites the delivery of transformative therapies.
A new discovery about the dynamic structure of norovirus particles has implications for vaccine development.
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.